Tvardi Therapeutics, Inc.
TVRD
$3.98
$0.020.51%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.16% | -4.68% | 165.04% | 371.23% | 70.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.94% | -29.76% | 4.62% | 23.51% | -2.11% |
| Operating Income | -61.94% | 29.76% | -4.62% | -23.51% | 2.11% |
| Income Before Tax | 28.97% | 42.75% | -0.25% | 159.74% | -127.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.97% | 42.75% | -0.25% | 159.74% | -127.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.97% | 42.75% | -0.25% | 159.74% | -127.96% |
| EBIT | -61.94% | 29.76% | -4.62% | -23.51% | 2.11% |
| EBITDA | -62.29% | 29.83% | -4.64% | -23.58% | 2.12% |
| EPS Basic | 80.50% | 84.29% | 72.47% | 118.65% | -465.93% |
| Normalized Basic EPS | 80.50% | 84.29% | 72.47% | 118.65% | -466.01% |
| EPS Diluted | 80.50% | 84.30% | 72.45% | 62.94% | -465.93% |
| Normalized Diluted EPS | 80.50% | 84.29% | 72.47% | 118.19% | -466.01% |
| Average Basic Shares Outstanding | 264.25% | 264.33% | 264.19% | 220.28% | -59.72% |
| Average Diluted Shares Outstanding | 264.25% | 264.33% | 264.19% | 228.38% | -59.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |